Information from the abstract
Objective: Psoriasis, chronic inflammatory skin condition, affects millions worldwide. This study explored the potential benefits of cannabidiol (CBD) extract as an add-on treatment. Methods: Thirty-four participants with mild psoriasis received either sublingual CBD extract or placebo daily for 12 weeks, followed by a washout period and crossover to the opposite treatment for another 12 weeks. The primary outcome was the change in Psoriasis Area and Severity Index (PASI) score. The secondary outcomes were safety, quality of life, and treatment cost. Results: No statistically significant difference in PASI score change was observed between CBD (3.76 ±4.07) and placebo (2.99 ± 2.91) at weeks 12; P=0.392. However, the CBD group exhibited significantly decrease alkaline phosphatase (-9.17IU/L [-12.85, -5.49]; P
Why this record is monitored
This record has an Impact Signal of 81/100 based on recency, source, collaboration, and bibliographic signals. It prioritizes monitoring and is not a judgment of research quality.
Related topics: Psoriasis: Treatment and Pathogenesis · Cannabis and Cannabinoid Research · Dermatology and Skin Diseases
Thai researcher and institutional participation
Theerada Taesotikul · Narisa Ruenroengbun · Silpakorn University
Data limitations
This page is a bibliographic record based on abstract-level information, not a full analysis or quality assessment. Verify the DOI and original article before citation.